Dendreon

Dendreon is a leading biopharmaceutical company at the forefront of immunotherapy development, dedicated to transforming cancer care. With a focus on innovation and patient outcomes, Dendreon is committed to pioneering new therapies that harness the power of the immune system to fight cancer. Dendreon's flagship product, PROVENGE (sipuleucel-T), represents a breakthrough in personalized cancer treatment, offering new hope for patients. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010.

Headquartered in Seal Beach, CA, at 1700 Saturn Way, Seal Beach, CA 90740, US, Dendreon operates with a commitment to excellence and a vision for a future where cancer is effectively managed through innovative immunotherapeutic approaches. With additional locations at 6715 Oakley Industrial Blvd, Union City, Georgia 30291, US, and 1208 Eastlake Ave E, Seattle, Washington, US, Dendreon's reach extends across the nation, impacting the lives of countless patients and families.

Dendreon is dedicated to expanding the applications of PROVENGE and exploring new avenues for immunotherapy in early-stage prostate cancer, with the ultimate goal of improving patient outcomes and enhancing the quality of life for those affected by this disease. We invite the manager of Dendreon to create a customized and exclusive company showcase and product listing on our platform to further amplify Dendreon's impact and reach.